Market Cap 27.64B
Revenue (ttm) 5.15B
Net Income (ttm) 1.40B
EPS (ttm) N/A
PE Ratio 18.89
Forward PE 18.28
Profit Margin 27.22%
Debt to Equity Ratio 0.06
Volume 1,734,500
Avg Vol 1,330,020
Day's Range N/A - N/A
Shares Out 145.06M
Stochastic %K 8%
Beta 0.84
Analysts Sell
Price Target $264.92

Company Profile

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry,...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 858-836-5000
Address:
9001 Spectrum Center Boulevard, San Diego, United States
RogueFF7
RogueFF7 Jun. 2 at 1:16 PM
$IXHL $RMD CPAP works, but one glove doesn’t fit all. If adherence weren’t a major issue, even companies like ResMed wouldn’t be actively exploring pharmacologic and alternative treatment pathways in sleep apnea. Critics tend to frame this as if the debate is purely “CPAP works vs CPAP doesn’t work.” That misses the real issue: CPAP efficacy is strong in controlled use, but real-world adherence remains a persistent limitation across a large portion of OSA patients. And this isn’t just theory. Sleep medicine experts with affiliations to ResMed have participated in advisory roles for emerging OSA programs, including Incannex’s IHL-42X initiative. Dr. Alison Wimms was cited in that context as representing ResMed in an advisory capacity at the time of that engagement. So it’s not “CPAP is threatened” It’s that the market itself acknowledges a gap between clinical efficacy and real-world treatment coverage.
1 · Reply
macdub8
macdub8 Jun. 2 at 12:12 PM
$RMD $IXHL maybe..but my post about RMD being done 35% since August and having 15b of its cap wiped is not delusion Its facts
1 · Reply
StrayTrader
StrayTrader Jun. 2 at 11:19 AM
$RMD the overwhelming number of Incannex ($IXHL) posts on here are delusional. Apnea is largely a mechanical obstruction. Maybe some of the mildest cases can be remediated by the component cannabinoid and ventilatory stabilization drugs, but the vast majority, and the more serious cases, cannot be. Mechanical obstruction requires mechanical,intervention. Oversized uvula, tonsils, palate or tongue and narrowed airways due to obesity cannot be changed by this pill. The efficacy of CPAP is superb in this area. Neither GLP-1’s nor some cannabinoid are going to change that. ResMed has been beaten down here. Stop wasting your time with your penny stock, and buy discounted shares of RMD instead.
2 · Reply
flychicken1991
flychicken1991 Jun. 1 at 8:09 PM
$RMD news impact: ResMed completed its Noctrix Health acquisition, adding prescription therapy for restless legs syndrome to its sleep-health portfolio and broadening its beyond-CPAP product mix. NewsImpact map: https://clawpool.hihired.org/newsimpact/?ticker=RMD&utm_source=stocktwits&utm_medium=parent_url Watch integration timing, payer coverage, sleep-portfolio cross-sell, GLP-1 apnea narrative, and margin impact. Not financial advice.
0 · Reply
macdub8
macdub8 Jun. 1 at 10:47 AM
$IXHL $RMD stock price is down 35% since August 2025..around $15B of its market cap wiped to date. The tape shows a sustained and gradual pull back (i.e. institutions pulling out gradually without shocking SP). This isn't a hate post on RMD..its purely to show that its abundantly clear the market is orientating more towards alternative therapies such as IXHL-42 and Api. It also blows up the 'medical advice' PR driven words from RMD that CPAP machines would always remain the gold theory...the market is voting with their feet
0 · Reply
StrayTrader
StrayTrader May. 30 at 1:46 AM
$RMD CPAP therapy gives immediate near total relief from apnea events, which are dangerous and serious, and can happen once per minute in severe cases. No pill, oral device or substitute therapy comes close. Lose weight? Sure, can take months. Meanwhile, you’re stressing your heart and brain with hypoxia and choking. Ridiculous. And the fundamentals prove it.
0 · Reply
StrayTrader
StrayTrader May. 29 at 7:06 PM
$RMD selloff is not warranted. The GLP-1 narrative is overdone and has not proven out in the company’s results. Sub 200 is a buy here.
1 · Reply
Jorwax
Jorwax May. 29 at 4:31 PM
$RMD 52 week low buy sell high
0 · Reply
Bong_PreahChan
Bong_PreahChan May. 29 at 1:16 AM
$IXHL $RMD this 💯👇 Refreshing to get a balanced opinion on this thread
0 · Reply
nobodyyk
nobodyyk May. 28 at 4:39 PM
$IXHL $RMD the agent in question is claude
0 · Reply
Latest News on RMD
ResMed price target lowered to $225 from $254 at Baird

2026-05-01T14:35:07.000Z - 4 weeks ago

ResMed price target lowered to $225 from $254 at Baird


ResMed price target lowered to $235 from $265 at Stifel

2026-05-01T11:18:33.000Z - 4 weeks ago

ResMed price target lowered to $235 from $265 at Stifel


ResMed beats quarterly profit estimates, names new CFO

Apr 30, 2026, 6:21 PM EDT - 4 weeks ago

ResMed beats quarterly profit estimates, names new CFO


ResMed Earnings Call Transcript: Q3 2026

Apr 30, 2026, 4:30 PM EDT - 4 weeks ago

ResMed Earnings Call Transcript: Q3 2026


ResMed Earnings release: Q3 2026

Apr 30, 2026, 4:30 PM EDT - 4 weeks ago

ResMed Earnings release: Q3 2026


ResMed Slides: Q3 2026

Apr 30, 2026, 4:30 PM EDT - 4 weeks ago

ResMed Slides: Q3 2026


ResMed Quarterly report: Q3 2026

Apr 30, 2026, 4:30 PM EDT - 4 weeks ago

ResMed Quarterly report: Q3 2026


ResMed reports Q3 EPS $2.86, consensus $2.72

2026-04-30T20:20:36.000Z - 4 weeks ago

ResMed reports Q3 EPS $2.86, consensus $2.72


ResMed price target lowered to $290 from $302 at KeyBanc

2026-04-27T10:25:52.000Z - 5 weeks ago

ResMed price target lowered to $290 from $302 at KeyBanc


ResMed initiated with an Overweight at JPMorgan

2026-04-15T15:25:36.000Z - 6 weeks ago

ResMed initiated with an Overweight at JPMorgan


ResMed price target lowered to $255 from $300 at Evercore ISI

2026-04-13T14:45:22.000Z - 7 weeks ago

ResMed price target lowered to $255 from $300 at Evercore ISI


ResMed price target lowered to $340 from $345 at Citi

2026-04-09T10:35:37.000Z - 7 weeks ago

ResMed price target lowered to $340 from $345 at Citi


ResMed At $250: Missed Opportunity Or A Trap In The Making?

Feb 25, 2026, 12:56 PM EST - 3 months ago

ResMed At $250: Missed Opportunity Or A Trap In The Making?


ResMed opens new distribution center in Greenwood, Indiana

2026-02-24T14:11:51.000Z - 3 months ago

ResMed opens new distribution center in Greenwood, Indiana


ResMed price target raised to $345 from $330 at Citi

2026-02-02T11:56:46.000Z - 4 months ago

ResMed price target raised to $345 from $330 at Citi


ResMed price target raised to $314 from $311 at RBC Capital

2026-01-30T12:55:16.000Z - 4 months ago

ResMed price target raised to $314 from $311 at RBC Capital


ResMed price target raised to $302 from $299 at KeyBanc

2026-01-30T12:46:57.000Z - 4 months ago

ResMed price target raised to $302 from $299 at KeyBanc


ResMed price target raised to $265 from $260 at Stifel

2026-01-30T12:46:41.000Z - 4 months ago

ResMed price target raised to $265 from $260 at Stifel


ResMed price target raised to $281 from $275 at Baird

2026-01-30T12:40:09.000Z - 4 months ago

ResMed price target raised to $281 from $275 at Baird


ResMed price target raised to $275 from $270 at Piper Sandler

2026-01-30T12:05:31.000Z - 4 months ago

ResMed price target raised to $275 from $270 at Piper Sandler


ResMed Earnings Call Transcript: Q2 2026

Jan 29, 2026, 4:30 PM EST - 4 months ago

ResMed Earnings Call Transcript: Q2 2026


ResMed Quarterly report: Q2 2026

Jan 29, 2026, 4:30 PM EST - 4 months ago

ResMed Quarterly report: Q2 2026


ResMed Earnings release: Q2 2026

Jan 29, 2026, 4:30 PM EST - 4 months ago

ResMed Earnings release: Q2 2026


ResMed Slides: Q2 2026

Jan 29, 2026, 4:30 PM EST - 4 months ago

ResMed Slides: Q2 2026


ResMed Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 1:30 PM EST - 5 months ago

ResMed Transcript: 44th Annual J.P. Morgan Healthcare Conference


ResMed Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 1:30 PM EST - 5 months ago

ResMed Slides: 44th Annual J.P. Morgan Healthcare Conference


IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

Nov 24, 2025, 2:15 PM EST - 6 months ago

IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

IDXX


ResMed Transcript: AGM 2025

Nov 19, 2025, 6:00 PM EST - 6 months ago

ResMed Transcript: AGM 2025


ResMed Earnings Call Transcript: Q1 2026

Oct 30, 2025, 4:30 PM EDT - 7 months ago

ResMed Earnings Call Transcript: Q1 2026


ResMed Quarterly report: Q1 2026

Oct 30, 2025, 4:30 PM EDT - 7 months ago

ResMed Quarterly report: Q1 2026


ResMed Earnings release: Q1 2026

Oct 30, 2025, 4:30 PM EDT - 7 months ago

ResMed Earnings release: Q1 2026


ResMed Slides: Q1 2026

Oct 30, 2025, 4:30 PM EDT - 7 months ago

ResMed Slides: Q1 2026


ResMed Proxy statement: Proxy Filing

Oct 2, 2025, 8:00 AM EDT - 8 months ago

ResMed Proxy statement: Proxy Filing


ResMed Proxy statement: Proxy Filing

Oct 2, 2025, 8:00 AM EDT - 8 months ago

ResMed Proxy statement: Proxy Filing


ResMed Slides: Corporate Presentation

Sep 18, 2025, 7:00 AM EDT - 9 months ago

ResMed Slides: Corporate Presentation


ResMed Slides: Sustainability Presentation

Sep 12, 2025, 7:00 AM EDT - 9 months ago

ResMed Slides: Sustainability Presentation


ResMed Earnings Call Transcript: Q4 2025

Jul 31, 2025, 4:30 PM EDT - 10 months ago

ResMed Earnings Call Transcript: Q4 2025


ResMed Annual report: Q4 2025

Jul 31, 2025, 4:30 PM EDT - 10 months ago

ResMed Annual report: Q4 2025


ResMed Earnings release: Q4 2025

Jul 31, 2025, 4:30 PM EDT - 10 months ago

ResMed Earnings release: Q4 2025


ResMed Slides: Q4 2025

Jul 31, 2025, 4:30 PM EDT - 10 months ago

ResMed Slides: Q4 2025


Spot Outliers Like ResMed Early with Money Flows

Jul 30, 2025, 6:08 AM EDT - 10 months ago

Spot Outliers Like ResMed Early with Money Flows


Resmed Acquires VirtuOx

May 1, 2025, 9:00 AM EDT - 1 year ago

Resmed Acquires VirtuOx


ResMed Earnings Call Transcript: Q3 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Earnings Call Transcript: Q3 2025


ResMed Quarterly report: Q3 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Quarterly report: Q3 2025


ResMed Earnings release: Q3 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Earnings release: Q3 2025


ResMed Slides: Q3 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Slides: Q3 2025


Jan De Witte joins GHO Capital as Operating Partner

Feb 11, 2025, 4:30 AM EST - 1 year ago

Jan De Witte joins GHO Capital as Operating Partner

IART


ResMed Earnings Call Transcript: Q2 2025

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Earnings Call Transcript: Q2 2025


ResMed Earnings release: Q2 2025

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Earnings release: Q2 2025


ResMed Quarterly report: Q2 2025

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Quarterly report: Q2 2025


ResMed Slides: Q2 2025

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Slides: Q2 2025


ResMed Slides: FY 2025

Jan 13, 2025, 6:00 PM EST - 1 year ago

ResMed Slides: FY 2025


ResMed Transcript: UBS Global Healthcare Conference 2024

Nov 12, 2024, 6:30 PM EST - 1 year ago

ResMed Transcript: UBS Global Healthcare Conference 2024


ResMed CEO On Earnings, Sleep Apnea

Oct 29, 2024, 11:23 AM EDT - 1 year ago

ResMed CEO On Earnings, Sleep Apnea


ResMed Proxy statement: Proxy Filing

Oct 25, 2024, 8:00 AM EDT - 1 year ago

ResMed Proxy statement: Proxy Filing


ResMed Earnings Call Transcript: Q1 2025

Oct 24, 2024, 4:30 PM EDT - 1 year ago

ResMed Earnings Call Transcript: Q1 2025


ResMed Quarterly report: Q1 2025

Oct 24, 2024, 4:30 PM EDT - 1 year ago

ResMed Quarterly report: Q1 2025


ResMed Earnings release: Q1 2025

Oct 24, 2024, 4:30 PM EDT - 1 year ago

ResMed Earnings release: Q1 2025


ResMed Slides: Q1 2025

Oct 24, 2024, 4:30 PM EDT - 1 year ago

ResMed Slides: Q1 2025


ResMed Proxy statement: Proxy Filing

Oct 3, 2024, 8:00 AM EDT - 1 year ago

ResMed Proxy statement: Proxy Filing


ResMed Proxy statement: Proxy Filing

Oct 3, 2024, 8:00 AM EDT - 1 year ago

ResMed Proxy statement: Proxy Filing


RogueFF7
RogueFF7 Jun. 2 at 1:16 PM
$IXHL $RMD CPAP works, but one glove doesn’t fit all. If adherence weren’t a major issue, even companies like ResMed wouldn’t be actively exploring pharmacologic and alternative treatment pathways in sleep apnea. Critics tend to frame this as if the debate is purely “CPAP works vs CPAP doesn’t work.” That misses the real issue: CPAP efficacy is strong in controlled use, but real-world adherence remains a persistent limitation across a large portion of OSA patients. And this isn’t just theory. Sleep medicine experts with affiliations to ResMed have participated in advisory roles for emerging OSA programs, including Incannex’s IHL-42X initiative. Dr. Alison Wimms was cited in that context as representing ResMed in an advisory capacity at the time of that engagement. So it’s not “CPAP is threatened” It’s that the market itself acknowledges a gap between clinical efficacy and real-world treatment coverage.
1 · Reply
macdub8
macdub8 Jun. 2 at 12:12 PM
$RMD $IXHL maybe..but my post about RMD being done 35% since August and having 15b of its cap wiped is not delusion Its facts
1 · Reply
StrayTrader
StrayTrader Jun. 2 at 11:19 AM
$RMD the overwhelming number of Incannex ($IXHL) posts on here are delusional. Apnea is largely a mechanical obstruction. Maybe some of the mildest cases can be remediated by the component cannabinoid and ventilatory stabilization drugs, but the vast majority, and the more serious cases, cannot be. Mechanical obstruction requires mechanical,intervention. Oversized uvula, tonsils, palate or tongue and narrowed airways due to obesity cannot be changed by this pill. The efficacy of CPAP is superb in this area. Neither GLP-1’s nor some cannabinoid are going to change that. ResMed has been beaten down here. Stop wasting your time with your penny stock, and buy discounted shares of RMD instead.
2 · Reply
flychicken1991
flychicken1991 Jun. 1 at 8:09 PM
$RMD news impact: ResMed completed its Noctrix Health acquisition, adding prescription therapy for restless legs syndrome to its sleep-health portfolio and broadening its beyond-CPAP product mix. NewsImpact map: https://clawpool.hihired.org/newsimpact/?ticker=RMD&utm_source=stocktwits&utm_medium=parent_url Watch integration timing, payer coverage, sleep-portfolio cross-sell, GLP-1 apnea narrative, and margin impact. Not financial advice.
0 · Reply
macdub8
macdub8 Jun. 1 at 10:47 AM
$IXHL $RMD stock price is down 35% since August 2025..around $15B of its market cap wiped to date. The tape shows a sustained and gradual pull back (i.e. institutions pulling out gradually without shocking SP). This isn't a hate post on RMD..its purely to show that its abundantly clear the market is orientating more towards alternative therapies such as IXHL-42 and Api. It also blows up the 'medical advice' PR driven words from RMD that CPAP machines would always remain the gold theory...the market is voting with their feet
0 · Reply
StrayTrader
StrayTrader May. 30 at 1:46 AM
$RMD CPAP therapy gives immediate near total relief from apnea events, which are dangerous and serious, and can happen once per minute in severe cases. No pill, oral device or substitute therapy comes close. Lose weight? Sure, can take months. Meanwhile, you’re stressing your heart and brain with hypoxia and choking. Ridiculous. And the fundamentals prove it.
0 · Reply
StrayTrader
StrayTrader May. 29 at 7:06 PM
$RMD selloff is not warranted. The GLP-1 narrative is overdone and has not proven out in the company’s results. Sub 200 is a buy here.
1 · Reply
Jorwax
Jorwax May. 29 at 4:31 PM
$RMD 52 week low buy sell high
0 · Reply
Bong_PreahChan
Bong_PreahChan May. 29 at 1:16 AM
$IXHL $RMD this 💯👇 Refreshing to get a balanced opinion on this thread
0 · Reply
nobodyyk
nobodyyk May. 28 at 4:39 PM
$IXHL $RMD the agent in question is claude
0 · Reply
WALLSTREETHAWK1
WALLSTREETHAWK1 May. 28 at 3:47 PM
$IXHL $RMD Spot on, Steph! You just exposed the entire whale game. Let’s break it down simply for everyone: The IXHL Volcano: Goldman Sachs (GSCO) is running a masterclass in price suppression. They are freezing the stock to force bored retail to quit, allowing big funds to quietly sweep up the tiny remaining float. High IV + High Days-to-Cover = a financial bomb waiting for the trigger. The RMD Panic: To anyone still posting RMD charts claiming they are the acquirer: You are reading the tape completely backwards. Look at the data. A freakish Put/Call Ratio of 709 is NOT the footprint of a buyer. If RMD were acquiring, institutional money would be buying Calls. Instead, they are aggressively buying massive insurance (Puts) to protect their billions. RMD isn't the hunter here they are the ones hiding in the bunker before the real alliance drops. When the news hits, the ask side will suffer a total liquidity void. This move is going to be violent. Great eye, Steph
1 · Reply
eyeexaechell
eyeexaechell May. 28 at 3:19 PM
$IXHL $RMD fanfiction
0 · Reply
RollTheDice369
RollTheDice369 May. 28 at 3:09 PM
$IXHL $RMD GSCO is placing blocks of 1,500–4,400 shares in L2 at a wide spread, while other market makers are at 100–200. Accumulation? They’ve been on the order book since RS, so if this were accumulation, they would have bought the entire IXHL long ago in a hostile takeover. I’m not reading any further.
0 · Reply
WickedEntry
WickedEntry May. 28 at 3:04 PM
$IXHL $RMD from one of my agents: I agree the structure around IXHL looks unusual for a microcap biotech. The options activity, IV behavior, and tighter tape action suggest larger participants are involved beyond pure retail. But I’d be careful jumping straight from “unusual market structure” to “hidden M&A accumulation.” GSCO activity could mean: accumulation market making warrant hedging liquidity management structured financing flows High IV + suppressed price can also happen naturally in biotech when: dilution fears exist shorts stay active investors distrust management traders hedge volatility The low float + high days-to-cover setup IS important though. If sentiment flips on strong DReAMzz progress/data, the move could become violent very quickly. I think the strongest takeaway is: IXHL no longer trades like a random dead retail penny biotech. But the real catalyst still has to be: strong execution clean data financing stability institutional confidence rebuilding.
2 · Reply
RollTheDice369
RollTheDice369 May. 28 at 3:04 PM
0 · Reply
Mamalama
Mamalama May. 28 at 2:49 PM
$IXHL $RMD is this Rvn9
1 · Reply
Steph61
Steph61 May. 28 at 2:44 PM
$IXHL $RMD Is there anyone of intelligence on this board that can take a look at what I described below?
1 · Reply
Steph61
Steph61 May. 28 at 1:59 PM
$IXHL $RMD RMD’s chain is behaving like institutional risk transfer. Look at the strikes. Look at the IV curvature. Look at how liquidity appears only where large capital would actually need protection. Retail doesn’t build volatility architecture like this. Market makers don’t waste balance sheet creating rails for bored gamblers. Then look at IXHL’s tape GSCO sitting there for months, suppressed price despite extreme IV, low-float structure, unusually high days-to-cover, controlled spreads instead of chaotic panic
0 · Reply
BillionerOfKing
BillionerOfKing May. 27 at 2:23 PM
$RMD Current Stock Price: $211.16 Contracts to trade: $210.0 RMD Jun 18 2026 Call Entry: $4.60 Exit: $7.83 ROI: 70% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
CapitalMonk
CapitalMonk May. 25 at 9:54 PM
$RMD Price: $208.05 (-0.45%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±2.81% RSI: 48.8 | Momentum: Moderate Volume: -27.6% vs avg Volatility: 1.83% Support: $198.02 | Resistance: $223.26 Sourch: http://marketbaubles.com/
0 · Reply
CapitalMonk
CapitalMonk May. 21 at 10:03 PM
$RMD Price: $208.98 (-0.42%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±2.55% RSI: 56.5 | Momentum: Moderate Volume: -49.7% vs avg Volatility: 1.83% Support: $198.02 | Resistance: $223.26 Sourch: http://marketbaubles.com/
0 · Reply
Dr_Stoxx
Dr_Stoxx May. 19 at 2:46 PM
$RMD was mentioned last week as a solid value play after I heard about it in my pro group (one guy, buying leaps)...and I'm still not sure why it's been so out of favor. Today it is breaking the long downtrend on good volume. Not a 5-step setup, even in modified form, but possibly a good add to your long-term value holdings. I bought some myself on that mention.
0 · Reply